Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 16/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485253 | 0.91 | EPHB4 (0.51) | EPHB4AURKAKDM4EALDH1A1POLB | |
| SCHEMBL5478264 | 0.89 | EPHB4 (0.57) | EPHB4AURKAKDM4EALDH1A1POLB | |
| SCHEMBL5478608 | 0.87 | EPHB4 (0.57) | EPHB4AURKAKDM4EALDH1A1POLB | |
| SCHEMBL5474240 | 0.82 | EPHB4 (0.54) | EPHB4AURKAKDM4EALDH1A1POLB | |
| SCHEMBL5485256 | 0.74 | EPHB4 (0.64) | EPHB4AURKA | |
| SCHEMBL5475356 | 0.73 | EPHB4 (0.63) | EPHB4 | |
| SCHEMBL5484746 | 0.73 | EPHB4 (0.58) | EPHB4AURKAKDM4EALDH1A1POLB | |
| SCHEMBL5477695 | 0.72 | AURKA (0.63) | EPHB4AURKA | |
| SCHEMBL5478220 | 0.72 | EPHB4 (0.54) | EPHB4AURKAKDM4EALDH1A1POLB | |
| SCHEMBL5477968 | 0.70 | EPHB4 (0.56) | EPHB4AURKAKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312341-B2 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | claimed |
| WO-2004022562-A1 | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-7312341-B2 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004022562-A1 | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, PRKACA, MAP3K1 | EPHB4 4062/4885AURKA 207/4885KDM4E 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.